tradingkey.logo

Opthea Ltd

OPT
0.000
Close 12/08, 16:00ETQuotes delayed by 15 min
--Market Cap
--P/E TTM

Opthea Ltd

0.000
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison

TradingKey Stock Score of Opthea Ltd

Currency: USD Updated: 2025-10-27

Key Insights

Its valuation is considered fairly valued, Institutional ownership is very high.Over the past month, multiple analysts have rated it as Sell, with the highest price target at max_target_price.

Opthea Ltd's Score

Industry at a Glance

Industry Ranking
313 / 501
Overall Ranking
648 / 4682
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Analyst Rating

Based on 2 analysts
Sell
Current Rating
1.000
Target Price
-70.67%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Opthea Ltd Highlights

StrengthsRisks
Opthea Limited is an Australia-based clinical-stage biopharmaceutical company. The Company is engaged in developing novel therapies to address the unmet need in the treatment of prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Its lead product candidate, sozinibercept (OPT-302), is being evaluated in two pivotal Phase 3 clinical trials for use in combination with standard-of-care anti-VEGF-A monotherapies for the treatment of wet AMD and DME. The Company has also manufactured OPT-302 for use in Phase III clinical trials, conducts activities to support the commercialization of the product and expanded its management team in the United States to facilitate broader oversight and execution of its Phase III program. Its development activities are based on an intellectual property portfolio covering key targets (Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3).
Growing
The company is in a growing phase, with the latest annual income totaling USD 59.09K.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 59.09K.
Fairly Valued
The company’s latest PE is 0.00, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 7.74M shares, decreasing 19.40% quarter-over-quarter.

Financial Health

Currency: USD Updated: 2025-10-27

No financial score is currently available for Opthea Ltd. The Biotechnology & Medical Research industry's average is 6.92.

Score

Industry at a Glance

Previous score
0.00
Change
0

Financials

Key Metrics

Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.

Quality of Earnings

Operational Efficiency

Growth Potential

Shareholder Returns

Opthea Ltd's Company Valuation

Currency: USD Updated: 2025-10-27

No valuation score is currently available for Opthea Ltd. The Biotechnology & Medical Research industry's average is 6.98. Its current P/E ratio is 0.00, which is NaN% below the recent high of 0.00 and +Inf% above the recent low of -19.36.

Score

Industry at a Glance

Previous score
0.00
Change
0

Valuation Dimensions

P/E
P/B
P/S
P/CF
Industry Ranking 313/501
Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2025-10-27

The current earnings forecast score of Opthea Ltd is 4.00, ranking industry_rank/industry_total in the Biotechnology & Medical Research industry. The average price target for Opthea Ltd is 1.00, with a high of 1.00 and a low of 1.00.

Score

Industry at a Glance

Previous score
4.00
Change
0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 2 analysts
Sell
Current Rating
1.000
Target Price
-70.67%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

523
Total
6
Median
6
Average
Company name
Ratings
Analysts
Opthea Ltd
OPT
2
CRISPR Therapeutics AG
CRSP
30
Intellia Therapeutics Inc
NTLA
25
IQVIA Holdings Inc
IQV
25
argenx SE
ARGX
25
Ionis Pharmaceuticals Inc
IONS
24
1
2
3
...
105

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-27

The current price momentum score of Opthea Ltd is 1.00, ranking industry_rank/industry_total in the Biotechnology & Medical Research industry.

Score

Industry at a Glance

Previous score
1.00
Change
0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(1)
Neutral(2)
Buy(0)
Indicators
Value
Direction
MACD(12,26,9)
0.000
Neutral
RSI(14)
15.773
Oversold
STOCH(KDJ)(9,3,3)
0.000
Oversold
ATR(14)
-0.000
Low Volatility
CCI(14)
0.000
Neutral
Williams %R
0.000
Overbought
TRIX(12,20)
-14.439
Sell
StochRSI(14)
0.000
Oversold
Moving Average
Sell(2)
Neutral(0)
Buy(4)
Indicators
Value
Direction
MA5
-0.000
Buy
MA10
0.000
Sell
MA20
-0.000
Buy
MA50
-0.000
Buy
MA100
-0.000
Buy
MA200
0.629
Sell

Institutional Confidence

Currency: USD Updated: 2025-10-27

Score

Industry at a Glance

Previous score
3.00
Change
0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name
Shares Held
Chg %
Regal Partners Limited
5.19M
--
Baker Bros. Advisors LP
2.09M
--
Pengana Capital Group Limited
270.42K
--
HSBC Global Asset Management (UK) Limited
105.94K
--
Millennium Management LLC
48.33K
--
UBS Financial Services, Inc.
7.77K
--
EP Wealth Advisors, LLC
10.00K
--
Geode Capital Management, L.L.C.
5.05K
--
Morgan Stanley Smith Barney LLC
765.00
--
Susquehanna International Group, LLP
--
-100.00%
1
2

Risk Assessment

Currency: USD Updated: 2025-10-27

No risk assessment score is currently available for Opthea Ltd. The Biotechnology & Medical Research industry's average is 3.49.

Score

Industry at a Glance

Previous score
0.00
Change
0
Beta vs S&P 500 index
--
VaR
--
240-Day Maximum Drawdown
+100.00%
240-Day Volatility
--

Return

Best Daily Return
60 days
--
120 days
--
5 years
--
Worst Daily Return
60 days
--
120 days
--
5 years
--
Sharpe Ratio
60 days
--
120 days
--
5 years
--

Risk Assessment

Maximum Drawdown
240 days
+100.00%
3 years
+100.00%
5 years
+100.00%
Return-to-Drawdown Ratio
240 days
-1.00
3 years
-0.33
5 years
-0.20
Skewness
240 days
--
3 years
--
5 years
--

Volatility

Realised Volatility
240 days
--
5 years
--
Standardised True Range
240 days
--
5 years
--
Downside Risk-Adjusted Return
120 days
--
240 days
--
Maximum Daily Upside Volatility
60 days
--
Maximum Daily Downside Volatility
60 days
--

Liquidity

Average Turnover Rate
60 days
--
120 days
--
5 years
--
Turnover Deviation
20 days
--
60 days
--
120 days
--

Peer Comparison

Biotechnology & Medical Research
Opthea Ltd
Opthea Ltd
OPT
1.30 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQVIA Holdings Inc
IQV
8.77 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Zymeworks Inc
Zymeworks Inc
ZYME
8.58 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
Krystal Biotech Inc
KRYS
8.54 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BioCryst Pharmaceuticals Inc
BCRX
8.51 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Amicus Therapeutics Inc
Amicus Therapeutics Inc
FOLD
8.51 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more

FAQs

How does TradingKey generate the Stock Score of Opthea Ltd?

The TradingKey Stock Score provides a comprehensive assessment of Opthea Ltd based on 34 indicators derived from over 100 underlying data points.
These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Opthea Ltd’s performance and outlook.

How do we generate the financial health score of Opthea Ltd?

To generate the financial health score of Opthea Ltd, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns.
By integrating these comprehensive data, the financial health score not only reflects Opthea Ltd's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Opthea Ltd.

How do we generate the company valuation score of Opthea Ltd?

To generate the company valuation score of Opthea Ltd, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Opthea Ltd’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value.
By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Opthea Ltd’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Opthea Ltd.

How do we generate the earnings forecast score of Opthea Ltd?

To calculate the earnings forecast score of Opthea Ltd, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:
Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.
Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.
By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.
Comparing these indicators against peers provides context for the stock’s performance and helps anchor more realistic expectations.
These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Opthea Ltd’s future.

How do we generate the price momentum score of Opthea Ltd?

When generating the price momentum score for Opthea Ltd, we examine momentum indicators including support and resistance levels as well as volume metrics.
Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.
This comprehensive approach can reflect market sentiment and enable rational forecasts of Opthea Ltd’s prices. A higher score indicates a more stable short-term price trend for Opthea Ltd.

How do we generate the institutional confidence score of Opthea Ltd?

To generate the institutional confidence score of Opthea Ltd, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Opthea Ltd’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Opthea Ltd.

How do we generate the risk management score of Opthea Ltd?

To assess the risk management score of Opthea Ltd, we examine multiple key indicators related to returns, risk, volatility, and liquidity.
The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.
These indicators together provide a multi-dimensional understanding of Opthea Ltd’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Opthea Ltd.
KeyAI